ZURICH—Novartis has signed an option, collaboration, and license agreement with BeiGene Ltd for anti-cancer therapy ociperlimab (BGB-A1217) to expand its activities in immuno-oncology, the Swiss drugmaker said on Monday. Under terms of the agreement, Novartis will make an upfront payment to BeiGene of $300 million and pay a fee of up to $700 million if…